Annals of Surgical Oncology

, Volume 18, Issue 3, pp 805–812 | Cite as

Impact of uPA System Gene Polymorphisms on the Susceptibility of Environmental Factors to Carcinogenesis and the Development of Clinicopathology of Oral Cancer

  • Chia-Jui Weng
  • Chiao-Wen Lin
  • Tsung-Te Chung
  • Chiung-Man Tsai
  • Mu-Kuan ChenEmail author
  • Shun-Fa YangEmail author
Head and Neck Oncology



The levels of urokinase plasminogen activator (uPA) system in tumor tissues are implicated as prognostic biomarkers in a wide range of malignancies. However, their possible impact on the risk and prognosis of oral cancer and the susceptibility of environmental carcinogens to oral cancer remains poorly investigated.


The genetic polymorphisms of uPA, uPA receptor (uPAR), and plasminogen activator inhibitor (PAI)-1 were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 253 patients with oral cancer and 344 healthy controls.


There was no significant effect of uPA system genes on the susceptibility of oral cancer; however, the impact of uPA system gene polymorphisms on the susceptibility of betel nut and tobacco consumptions to oral cancer was revealed, except for that of uPAR gene polymorphism on tobacco consumption. Patients with oral cancer with at least one 5G allele of PAI-1 gene have a low risk for the development of clinical stage III or IV (p ≤ 0.05) and lymph node metastasis (p ≤ 0.05) compared with those with 4G/4G homozygotes.


Our results suggest that the combination of uPA system gene polymorphisms and environmental carcinogens was related to the risk of oral cancer, and the genetic polymorphism of PAI-1 was associated with a low risk to the clinicopathological development of oral cancer.


Oral Cancer Oral Squamous Cell Carcinoma Oral Squamous Cell Carcinoma Tobacco Consumption Environmental Carcinogen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was supported by a research grant from National Science Council, Taiwan (NSC98-2314-B-317-003-MY3). PCR was performed in the Instrument Center of Chung Shan Medical University, which is supported by National Science Council, Ministry of Education and Chung Shan Medical University.


  1. 1.
    Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003;22:205–22.PubMedCrossRefGoogle Scholar
  2. 2.
    Duffy MJ, Maguire TM, McDermott EW, O’Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol. 1999;71:130–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg. 2002;26:767–71.PubMedCrossRefGoogle Scholar
  4. 4.
    Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep. 2005;14:105–12.PubMedGoogle Scholar
  5. 5.
    Sakakibara T, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K, Nakao A. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer. 2005;93:799–803.PubMedCrossRefGoogle Scholar
  6. 6.
    Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008;34:122–36.PubMedCrossRefGoogle Scholar
  7. 7.
    Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Duggan C, Kennedy S, Kramer MD, et al. Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer. 1997;76:622–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Fredstorp-Lidebring M, Bendahl PO, Brunner N, et al. Urokinase plasminogen activator and its inhibitor PAI-1, in association with progression-free survival in early stage endometrial cancer. Eur J Cancer. 2001;37:2339–48.PubMedCrossRefGoogle Scholar
  10. 10.
    Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001;93:913–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Yang SF, Yang WE, Chang HR, Chu SC, Hsieh YS. Luteolin induces apoptosis in oral squamous cancer cells. J Dent Res. 2008;87:401–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Biolchini F, Pollastri G, Figurelli S, Chiarini L. Carcinogen metabolism, DNA damage repair and oral head and neck squamocellular carcinoma (HNSCC). Minerva Stomatol. 2005;54:405–14.PubMedGoogle Scholar
  13. 13.
    Nagaraj NS, Beckers S, Mensah JK, Waigel S, Vigneswaran N, Zacharias W. Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. Toxicol Lett. 2006;165:182–94.PubMedCrossRefGoogle Scholar
  14. 14.
    Lai KC, Lee TC. Genetic damage in cultured human keratinocytes stressed by long-term exposure to areca nut extracts. Mutat Res. 2006;599:66–75.PubMedGoogle Scholar
  15. 15.
    Yen CY, Liu SY, Chen CH, et al. Combinational polymorphisms of four DNA repair genes XRCC1, XRCC2, XRCC3, and XRCC4 and their association with oral cancer in Taiwan. J Oral Pathol Med. 2008;37:271–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Vairaktaris E, Yapijakis C, Serefoglou Z, et al. The interleukin-10 (−1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. Anticancer Res. 2008;28:309–14.PubMedGoogle Scholar
  17. 17.
    Teng YH, Liu TH, Tseng HC, et al. Contribution of genetic polymorphisms of stromal cell-derived factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. Head Neck. 2009;31:1282–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Xu J, Li W, Bao X, et al. Association of putative functional variants in the PLAU gene and the PLAUR gene with myocardial infarction. Clin Sci (Lond). 2010;119:353–9.CrossRefGoogle Scholar
  19. 19.
    de Haas EC, Zwart N, Meijer C. Association of PAI-1 gene polymorphism with survival and chemotherapy-related vascular toxicity in testicular cancer. Cancer. 2010 (in press).Google Scholar
  20. 20.
    Chen MK, Tsai HT, Chung TT, et al. Glutathione S-transferase P1 and alpha gene variants; role in susceptibility and tumor size development of oral cancer. Head Neck. 2010;32:1079–87.PubMedCrossRefGoogle Scholar
  21. 21.
    Ghoshal S, Mallick I, Panda N, Sharma SC. Carcinoma of the buccal mucosa: analysis of clinical presentation, outcome and prognostic factors. Oral Oncol. 2006;42:533–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Nanbu R, Menoud PA, Nagamine Y. Multiple instability-regulating sites in the 30 untranslated region of the urokinase-type plasminogen activator mRNA. Mol Cell Biol. 1994;14:4920–8.PubMedGoogle Scholar
  23. 23.
    Lin MH, Wang CJ, Huang HP, Chou MY, Chou FP. The tumorigenic characteristics of lime-piper betel quid-transformed JB6 cells. Arch Toxicol. 2004;78:167–73.PubMedCrossRefGoogle Scholar
  24. 24.
    Lin PY, Yu CH, Wang JT, Chen HH, Cheng SJ, Kuo MY, Chiang CP. Expression of hypoxia-inducible factor-1 alpha is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. J Oral Pathol Med. 2008;37:18–25.PubMedCrossRefGoogle Scholar
  25. 25.
    Huang SF, Chen IH, Liao CT, Wang HM, Liou SH, Hsieh LL. Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol. 2009;45:16–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Chang KW, Lee TC, Yeh WI, Chung MY, Liu CJ, Chi LY, Lin SC. Polymorphism in heme oxygenase-1 (HO-1) promoter is related to the risk of oral squamous cell carcinoma occurring on male areca chewers. Br J Cancer. 2004;91:1551–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, Chang CS. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett. 2006;243:47–54.PubMedCrossRefGoogle Scholar
  28. 28.
    Sharma R, Ahuja M, Panda NK, Khullar M. Combined effect of smoking and polymorphisms in tobacco carcinogen-metabolizing enzymes CYP1A1 and GSTM1 on the head and neck cancer risk in North Indians. DNA Cell Biol. 2010;29:441–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Naina HV, Patnaik MM, Ali UA, Chen D, Ashrani AA. Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer. J Clin Oncol. 2010;28:e167–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Eriksson P, Kallin B, van’t Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92:1851–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Castelló R, Espana F, Vazquez C, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res. 2006;117:487–92.PubMedCrossRefGoogle Scholar
  32. 32.
    Chen YQ, Sloan-Lancaster J, Berg DT, Richardson MA, Grinnell B, Tseng-Crank J. Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells. Thromb Haemost. 2001;86:1563–72.PubMedGoogle Scholar
  33. 33.
    Swiatkowska M, Szemraj J, Cierniewski CS. Induction of PAI-1 expression by tumor necrosis factor alpha in endothelial cells is mediated by its responsive element located in the 4G/5G site. FEBS J. 2005;272:5821–31.PubMedCrossRefGoogle Scholar
  34. 34.
    Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991;17:303–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Nielsen HJ, Pappot H, Christensen IJ, et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. Br Med J. 1998;316:829–30.Google Scholar
  36. 36.
    Smolarz B, Blasiak J, Kulig A, et al. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J Exp Clin Cancer Res. 2001;20:247–52.PubMedGoogle Scholar
  37. 37.
    Loktionov A, Watson MA, Stebbings WS, Speakman CT, Bingham SA. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett. 2003;189:189–96.PubMedCrossRefGoogle Scholar
  38. 38.
    Alvarez-Millán JJ, Bocos C, Ferrín V, Lucas AR, Ruibal A, Schneider J. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells. Oncology. 2002;62:286–90.PubMedCrossRefGoogle Scholar
  39. 39.
    Manders P, Tjan-Heijnen VC, Span PN, et al. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Cancer. 2004;101:486–94.PubMedCrossRefGoogle Scholar
  40. 40.
    Sciacca FL, Ciusani E, Silvani A, et al. Genetic and plasma markers of venous thromboembolism in patients with high-grade glioma. Clin Cancer Res. 2004;10:1312–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Yasuda T, Sakata Y, Kitamura K, Morita M, Ishida T. Localization of plasminogen activators and their inhibitor in squamous cell carcinoma of the head and neck. Head Neck. 1997;19:611–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Curino A, Patel V, Nielsen BS, et al. Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. Oral Oncol. 2000;40:1026–32.CrossRefGoogle Scholar
  43. 43.
    Hundsdorfer B, Zeilhofer HF, Bock KP, et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal neoplastic tissues of patients with squamous cell cancer of the oral cavity: clinical relevance and prognostic value. Craniomaxillofac Surg. 2005;33:191–6.Google Scholar
  44. 44.
    Bajou K, Maillard C, Jost M, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene. 2004;23:6986–90.PubMedCrossRefGoogle Scholar
  45. 45.
    Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1–22.PubMedCrossRefGoogle Scholar
  46. 46.
    Czekay RP, Loskutoff DJ. Unexpected role of plasminogen activator 1 in cell adhesion and detachment. Exp Biol Med. 2004;229:1090–6.Google Scholar

Copyright information

© Society of Surgical Oncology 2010

Authors and Affiliations

  1. 1.Graduate Institute of Applied Science of LivingTainan University of TechnologyTainanTaiwan
  2. 2.Institute of Biochemistry and BiotechnologyChung Shan Medical UniversityTaichungTaiwan
  3. 3.Institute of MedicineChung Shan Medical UniversityTaichungTaiwan
  4. 4.Department of OtolaryngologyShow Chwan Memorial HospitalChanghuaTaiwan
  5. 5.Chest Hospital, Department of Health, Executive YuanTainanTaiwan
  6. 6.Department of Otorhinolaryngology-Head and Neck SurgeryChanghua Christian HospitalChanghuaTaiwan
  7. 7.School of MedicineChung Shan Medical UniversityTaichungTaiwan
  8. 8.Department of Medical ResearchChung Shan Medical University HospitalTaichungTaiwan

Personalised recommendations